Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 3/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.33 |
| ▸ | IL1RN | P18510 | 2/20 | 0.33 |
| ▸ | NPY4R | P50391 | 5/20 | 0.32 |
| ▸ | NPY1R | P25929 | 3/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20465433 | 0.83 | CTSB (0.37) | BIRC2ERAP2IL1RNNPY4RNPY1R | |
| SCHEMBL25488443 | 0.83 | NPY4R (0.35) | BIRC2ERAP2IL1RNNPY4RNPY1R | |
| SCHEMBL18476683 | 0.82 | MME (0.34) | BIRC2ERAP2NPY4RNPY1RFOLH1 | |
| SCHEMBL18478758 | 0.82 | ERAP2 (0.33) | BIRC2ERAP2FOLH1 | |
| SCHEMBL26946628 | 0.82 | MME (0.34) | BIRC2ERAP2NPY4RNPY1RFOLH1 | |
| SCHEMBL20465427 | 0.80 | CTSL (0.32) | BIRC2ERAP2FOLH1 | |
| SCHEMBL20468541 | 0.80 | ANPEP (0.32) | BIRC2ERAP2NPY4RNPY1RFOLH1 | |
| SCHEMBL18451208 | 0.80 | CTSL (0.32) | BIRC2ERAP2FOLH1 | |
| SCHEMBL24329140 | 0.79 | NPY1R (0.30) | NPY4RNPY1R | |
| SCHEMBL21473367 | 0.75 | L3MBTL1 (0.39) | BIRC2ERAP2IL1RNNPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738066-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738066-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | BIRC2 4883/4885ERAP2 3264/4885IL1RN 3309/4885 |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | BIRC2 4883/4885ERAP2 3264/4885IL1RN 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.